Baxter Healthcare Corporation, Onkotrone Injection 2 mg/ml concentrate for solution for infusion defect
Class 4 medicines defect notification: The MHRA has published a Class 4 medicines defect notification for Onkotrone Injection 2 mg/ml concentrate for solution for infusion.
Published: 18 March 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for Onkotrone Injection 2 mg/ml concentrate for solution for infusion.
Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in affected batches does not contain up to date information relating to the duration of contraception required for females after stopping taking this medication.
Further information, advice and details of the affected batches can be found on the MHRA website.